In terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held on Friday, July 25, 2025 considered and approved, the Unaudited Financial Results along with Limited Review Report of the Statutory Auditors thereon are enclosed herewith in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
RPGLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
RPG Life Sciences' Board approved Q1 FY26 (Apr-Jun 2025) unaudited results on July 25, 2025. Revenue from operations stood at Rs. 16,892 lakhs, up modestly by ~2.1% YoY from Rs. 16,542 lakhs in Q1 FY25. Profit after tax was Rs. 2,629 lakhs, slightly lower than Rs. 2,676 lakhs in the same quarter last year, with basic EPS of Rs. 15.90 (vs Rs. 16.18 YoY). A large exceptional gain of Rs. 10,990 lakhs was booked from the assignment of surplus vacant leasehold land along with built-up structures at MIDC, Navi Mumbai, which boosted reported PBT to Rs. 14,533 lakhs. The company also provided an update on the January 2025 fire at its API plant in Navi Mumbai — total estimated loss of Rs. 2,483 lakhs recognized as exceptional in Q4 FY25, with the insurer having released two interim payments totalling Rs. 850 lakhs. Statutory auditor S R B C & Co LLP issued an unqualified limited review report with no qualifications or adverse remarks.
Underlying business performance was largely flat with only marginal revenue and profit growth, but headline PAT got a significant one-time boost from the land monetization. Shareholders should view the land sale as a non-recurring windfall; the core pharma business showed stable but unspectacular growth this quarter. Clean audit report and no governance red flags.